

## SUBJECT INDEX—VOLUME 11, 2007

---

- Acetowhite areas, prevalence in male partners of women affected by HPV and SIL, 130(ab)
- Adenocarcinoma, cervical, prevalence of HPV types 16 and 18 in, 62(ab)
- Adenocarcinoma in situ (AIS)  
of cervix, efficacy of conization treatment for, 199(ab)  
women with, updated consensus guidelines for management of, 223
- Adolescents, CIN in, H & E-stained biopsies for evaluation of, p16 IHC for specificity in, 141
- American Society for Colposcopy and Cervical Pathology (ASCCP), Society news, 59, 127, 297
- Anogenital intraepithelial neoplasia, high-grade, noncervical, prime-boost vaccination strategy in women with, 62(ab)
- ASCUS-LSIL Triage Study (ALTS), on CIN3 risk during post-colposcopic follow-up, 64(ab), 195(ab)
- Atypical glandular cells (AGC) cytology, clinical significance of, 198(ab)
- Atypical squamous cells, cannot exclude HSIL (ASC-H), cumulative risk of CIN 2 and 3 in patients, 86
- Atypical squamous cells of undetermined significance (ASCUS) cytology, evolution of patients with, 198(ab)  
diagnosis of, 5  
HPV-DNA negative patients, and risk of HSIL in, 198(ab)  
women with abnormal cervical screening tests, updated consensus guidelines for management of, 201
- Biopsy histology, and Reid colposcopic index impression, correlation between, 147
- Blue nevi, of Müllerian tract, 284
- Breast cancer, isolated cervical metastasis of, 276
- Cancer  
breast, isolated cervical metastasis of, 276  
cervical  
among Appalachian women, Pap smear screening and colposcopy for, 251  
*DHFR* gene amplification and c-Myc overexpression for characterization of premalignant cervical lesions, 265  
HPV-induced, association of p16<sup>INK4A</sup> and FHIT expression, 151  
IFCPC terminology in prediction of, 158  
microinvasive  
in women from Grampian region, 290  
IA1 stage, conization for pelvic side wall recurrence after, 177  
p16 as marker for precursor lesions, 67 (editorial)  
prevention in the developing World, 273  
screening for managed care in, addition of HPV testing, cost effectiveness of, 258  
in Taiwan, efficacy and cost-effectiveness of nationwide screening, 193(ab)  
tissue spectroscopy for diagnosis of, 18  
endometrial, vulvar metastases of, surgical resection of, 118  
risk and presentation after colposcopic diagnosis of CIN 1 or less, 195(ab)  
screening among low-income women, improvement by telephone care management, 131(ab)  
of vulva  
clinical-pathological characteristics of, 199(ab)  
COX 2 expression in, 80  
poor agreement between vulvar cytology and biopsy, 8  
sentinel node (SN) biopsy in, 199(ab)
- Celecoxib, in treatment of cervical dysplasia, randomized double-blind placebo-controlled phase II trial of, 130(ab)
- Cervical adenocarcinoma, prevalence of HPV types 16 and 18 in, 62(ab)
- Cervical dysplasia, randomized double-blind placebo-controlled phase II trial of celecoxib in treatment of, 130(ab)
- Cervical intraepithelial neoplasia (CIN)  
in adolescents, H & E-stained biopsies for evaluation of, p16 IHC for specificity in, 141  
CIN 3  
cytological slides on cases of, 193(ab)  
risk and presentation after colposcopic diagnosis of CIN 1 or less, 195(ab)  
risk during postcolposcopic follow-up, ALTS report, 64(ab)  
COX 2 expression in, 80  
cumulative risk of CIN 2 and 3 in patients with ASC-H, 86  
gene expression profiling of women with, 25  
HPV testing after treatment of, cost effectiveness of, 301(ab)  
IFCPC terminology in prediction of, 158  
Langerhans' cells and smoking in, 63(ab)  
LEEP cervical conization, rare indication for 2-step discrepancy, 134  
low-grade, HPV DNA-negative, immunoeexpression of INK4A in, 98  
Nicaraguan women with, prevalence of high-risk HPV among, 61(ab)  
pathological discrepancy between Pap smear and cervical biopsy, LEEP for, 69  
uterine cervical carcinoma, in situ with replacement of corpus endometrium, 279  
in women with HIV, treatment of, 90  
women with, updated consensus guidelines for management of, 223

- Cervical metastasis, isolated, of breast cancer, 276
- Cervical neoplasia
- autoclave sterilization for eradication of HPV DNA on specula and instruments used for treatment, 12
  - DHFR* gene amplification and c-Myc overexpression, premalignant cervical lesions characterized by, 265
  - discontinuation of follow-up care, life stressors as reason for, 64(ab)
  - HPV testing and spectroscopy with cervical cytology for detection of, 73
  - spectroscopy for accurate detection of, 18
- Cervical smear, abnormal, in HMD, 274
- Cervical spectroscopy (CS), and HPV testing, with cervical cytology for detection of cervical neoplasia, 73
- Cervical stenosis, absence of endocervical cells on Pap smear after LEEP conization, marker for, 138
- Cervix
- adenocarcinoma in situ (AIS) of, updated consensus guidelines for management of, 223
  - Langerhans' cells and smoking in intraepithelial neoplasia of, 63(ab)
  - in situ adenocarcinoma of, efficacy of conization treatment for, 199(ab)
  - uterine
    - HPV DNA-negative, immunoexpression of INK4A in, 98
    - squamous intraepithelial lesions of, correlation of recurrence rates and times with posttreatment HPV status in patients treated with LEEP conization, 300(ab)
- Clinical Question: Ask the Expert, 122
- Colposcopy
- clinic nonattendance, impact of preclinic appointment telephone contact on, 35
  - at crossroads, 63(ab), 194(ab)
  - diagnosis of CIN 1 or less, risk and presentation of CIN 3 or cancer after, 195(ab)
  - evaluation of HPV 16 PCR detection in women referred for, 131(ab)
  - evaluation of patients with ASC-H by, CIN 2 or 3 detection during, 86
  - IFCPC terminology in prediction of cervical diseases, 158
  - music or guided imagery for patients undergoing, 39
  - or GOPD for abnormal menstrual bleeding, 108
  - and Pap smear screening, among Appalachian women, 251
  - Reid colposcopic index impression, and biopsy histology, correlation between, 147
- Conization
- for microinvasive cervical cancer stage IA1, pelvic side wall recurrence after, treatment without LVSI for, 177
  - treatment for in situ adenocarcinoma of cervix, efficacy of, 199(ab)
- Cyclooxygenase (COX 2) expression, in CIN and vulvar cancer, 80
- Dermatofibrosarcoma protuberans (DFSP), GCF as juvenile form of, 112
- Editorials, 1, 67
- EMG biofeedback, and lidocaine gel treatment for vulvar vestibulitis, efficacy of, 194(ab)
- Endometrial carcinoma, vulvar metastases of, surgical resection of, 118
- Endometrium, uterine cervical carcinoma in situ with replacement of, 279
- Fertility, preservation of fertility conization in patients with IA1 cervical cancers, treatment without LVSI, 177
- Fibroepithelial stromal polyp (FSP), differential diagnosis of, 112
- Fluorescence in situ hybridization (FISH), measurement of *DHFR* gene stability by, 265
- Fragile histidine triad (FHIT) expression, and HPV-induced cervical lesions, association of p16<sup>INK4A</sup>, 151
- Gene expression, profiling in women with cervical intraepithelial neoplasia, 25
- Giant cell fibroblastoma (GCF), of vulva at the site of previous cellular fibroepithelial stromal polyp, 112
- Hereditary mucoepithelial dysplasia (HMD), abnormal cervical smear in, 274
- Herpes simplex virus, genital mass in renal transplant recipient due to, 173
- HIV
- infection
    - no complication for diagnosis of vaginitis, 240
  - patients
    - with CIN, treatment of, 90
- Home study course
- fall 2007, 294
  - spring 2007, 123
  - summer 2007, 189
  - winter 2007, 55
- Host defense, innate, of vaginal and cervical human mucosae, 129(ab)
- Human mucosae, vaginal and cervical, innate host defense of, 129(ab)
- Human papillomavirus (HPV)
- abnormal pap tests and HPV in women tested for, preferences for sources of information, 131(ab)
  - assessment of patients knowledge on, 29
  - clearance in HIV patients, impact of smoking, 65(ab)
  - high-risk HPV, prevalence among women with cervical intraepithelial neoplasia, 61(ab)
  - HPV-16 and -18 prevalence in cervical adenocarcinoma, 62(ab)

- HPV DNA-negative normal and nonneoplastic cervical epithelia and low-grade SILs, immunoexpression of INK4A in, 98
- HPV-induced cervical lesions, association of p16<sup>INK4A</sup> and FHIT expression, 151
- HPV typing for analysis of multicentric intraepithelial female lower genital tract lesions, 300(ab)
- male partners of women affected by, prevalence of acetowhite areas in, 130(ab)
- PCR detection of HPV 16, 131(ab)
- posttreatment HPV status in uterine cervix SIL patients treated with LEEP conization, 300(ab)
- residual DNA on specula and instruments, autoclave sterilization for eradication of, 12
- testing
- after treatment of CIN, cost effectiveness of, 301(ab)
  - for managed care cervical cancer, cost effectiveness of, 258
  - and spectroscopy with cervical cytology for detection of cervical neoplasia, 73
  - in women with abnormal cervical screening tests, updated consensus guidelines for management of, 201
  - in urine, screening for detection of, 5
  - vaccine, high level of acceptance in midadult women, 166
- Human papillomavirus-like particles (HPV VLP), HPV-16 L1 VLP, cellular immunity to heterologous HPV types (HPV-18, HPV-31, and HPV-53), 61(ab)
- Hysterectomy, lower genital tract neoplasia after, vaginal vault smears for detection of, 129(ab)
- Intermenstrual bleeding (IMB), colposcopy or GOPD for, 108
- International Federation for Cervical Pathology and Colposcopy Terminology (IFCPC) terminology in prediction of cervical disease, 158
- International Society for the Study of Vulvovaginal Disease (ISSVD)
- classification of vulvar dermatoses by, 1 (editorial)
  - vulvar intraepithelial neoplasias, new ISSVD classification of, 46
  - vulvodynia, ISSVD terminology and classification of, 48
- Intraepithelial female lower genital tract lesions, multicentric, analysis by HPV typing and p16<sup>INK4a</sup> expression, 300(ab)
- Langerhans' cells, and smoking in intraepithelial neoplasia of cervix, 63(ab)
- Letter to the Editor, 200, 273
- Lidocaine gel, and EMG biofeedback, treatment for vulvar vestibulitis, efficacy of, 194(ab)
- Loop electrosurgical excision procedure (LEEP)
- absence of endocervical cells on Pap smear after, marker for cervical stenosis, 138
  - cervical conization, rare indication for 2-step discrepancy, 134
  - conization for cervical SILs, correlation of recurrence rates and times with posttreatment HPV status in patients treated with, 300(ab)
  - for diagnosis of CIN, 69
- Lower genital tract screening, brief history of, 182
- Lymph node metastasis (LNM), occurrence in IA1 cervical cancers, 177
- Menstrual bleeding, abnormal (PCB/IMB), colposcopy or GOPD for, 108
- Mucosae, human, vaginal and cervical, innate host defense of, 129(ab)
- Müllerian tract, Blue nevi of, 284
- Multicenter genital intraepithelial neoplasia syndrome, analysis by HPV typing and p16<sup>INK4a</sup> expression, 300(ab)
- New Zealand, cytological slides on CIN 3 from with, 193(ab)
- Nicaragua, prevalence of high-risk HPV among women with CIN in, 61(ab)
- p16
- IHC for specificity in H & E-stained biopsies evaluation of CIN in adolescents, 141
  - immunohistochemical expression in HPV DNA-negative normal and nonneoplastic cervical epithelia and low-grade SILs, 98
  - as marker for cervical cancer precursor lesions, 67 (editorial)
- p16<sup>INK4A</sup>
- association with FHIT expression and cervical lesions, 151
  - expression, and HPV typing, for analysis of multicenter genital intraepithelial neoplasia syndrome, 300(ab)
  - immunohistochemical expression in HPV DNA-negative normal and nonneoplastic cervical epithelia and low-grade SILs, 98
- Papanicolaou testing, among Vietnamese Americans, 65(ab)
- Pap (papanicolaou) smear
- after LEEP conization, absence of endocervical cells as marker for, 138
  - HPV knowledge in patients with history of, 29
  - screening, and colposcopy among Appalachian women, 251
- Pelvic side wall recurrence, after conization for microinvasive cervical cancer stage IA1, 177
- Postcoital bleeding (PCB), colposcopy or GOPD for, 108
- President's column, 3, 133
- Reid colposcopic index impression, and biopsy histology, correlation between, 147
- Renal transplantation, genital mass in recipient due to herpes simplex virus, 173
- Residual HPV DNA, autoclave sterilization for eradication of, 12

## Screening

- for cancer among low-income women, improvement by telephone care management, 131(ab)
- HPV detection in urine as alternative screening method for women, 5
- of lower genital tract, brief history of, 182
- for managed care cervical cancer, addition of HPV testing to, cost effectiveness of, 258
- nationwide, of cervical cancer in Taiwan, efficacy and cost-effectiveness of, 193(ab)
- Pap smear, and colposcopy among Appalachian women, 251
- women with abnormal cervical screening tests, updated consensus guidelines for management of, 201

Sentinel node (SN) biopsy in cancer of vulva, 199(ab)

## Smoking

- impact in intraepithelial neoplasia of cervix, 63(ab)
- impact on HPV clearance in HIV patients, 65(ab)

Society news, American Society for Colposcopy and Cervical Pathology (ASCCP), 59, 127, 297

Solitary fibrous tumors (SFTs), vaginal, 50

## Spectroscopy

- for accurate detection of cervical dysplasia, 18
- cervical spectroscopy (CS), and HPV testing, with cervical cytology for detection of cervical neoplasia, 73

Spindle cell sarcoma, of vagina, treatment with neoadjuvant radiation and pelvic exenteration for, 105

## Squamous intraepithelial lesions (SILs)

- cervical, endocervical gland involvement in, 63(ab)
- low-grade (LSIL), HPV DNA-negative, immunoexpression of INK4A in, 98
- male partners of women affected by, prevalence of acetowhite areas in, 130(ab)
- of uterine cervix, correlation of recurrence rates and times with posttreatment HPV status in patients treated with LEEP conization, 300(ab)
- women with abnormal cervical screening tests, updated consensus guidelines for management of, 201

Taiwan, nationwide cervical cancer screening in, efficacy and cost-effectiveness of, 193(ab)

## Tumors

- cervical metastasis of breast cancer, 276
- vulvar, giant vulvar lymphangioma circumscriptum mimicking, 281

Uterine cervical carcinoma in situ, with replacement of endometrium, 279

## Uterine cervix

- HPV DNA-negative, immunoexpression of p16<sup>INK4A</sup> in, 98

squamous intraepithelial lesions of, correlation of recurrence rates and times with posttreatment HPV status in patients treated with LEEP conization, 300(ab)

Vaccination, prime-boost vaccination strategy in women with anogenital intraepithelial neoplasia, 62(ab)

## Vaccines

HPV-16 L1 VLP, cellular immunity to heterologous HPV types (HPV-18, HPV-31, and HPV-53), 61(ab)

HPV vaccine, high level of acceptance in midadult women, 166

## Vagina

primary spindle cell sarcoma of, treatment with neoadjuvant radiation and pelvic exenteration, 105

solitary fibrous tumors of, 50

spindle cell lesions of, differential diagnosis of, 50

Vaginal intraepithelial neoplasia (VAIN), epidemiology and clinical characteristics of, 198(ab)

Vaginal vault smears, for detection of lower genital tract neoplasia after hysterectomy, 129(ab)

Vaginitis, standard diagnostic methods for, 240

Vietnamese Americans, papanicolaou testing among, 65(ab)

## Vulva

## cancer of

clinical-pathological characteristics of, 199(ab)

COX 2 expression in, 80

sentinel node (SN) biopsy in, 199(ab)

endometrial cancer recurrent to, surgical resection of, 118

giant cell fibroblastoma of, 112

Vulvar dermatoses, classification by ISSVD, 1 (editorial)

Vulvar dysplasia, correlation of cytological evaluation with histological diagnosis, 8

## Vulvar intraepithelial neoplasias (VINs)

new ISSVD classification of, 46

non-relevance of vulvar cytology in clinical management of, 8

Vulvar lymphangioma circumscriptum, giant, mimicking vulvar tumor, 281

Vulvar vestibulitis, EMG biofeedback vs. topical lidocaine gel treatment for, 194(ab)

Vulvodynia, ISSVD terminology and classification of, 48

## Women

with abnormal cervical screening tests, updated consensus guidelines for management of, 201

with CIN 3, cytological slides on cases of, 193(ab)

with CIN or AIS, updated consensus guidelines for management of, 223

with microinvasive cervical cancer in Grampian region, 290

midadult, high level of acceptance of HPV vaccine in, 166

with vulvar vestibulitis, EMG biofeedback vs. topical lidocaine gel treatment for, 194(ab)